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Abstract Objective To study the effects of Batroxobin on otitis media with effusion（OME）, an early stage of Adhe⁃
sive Otitis Media（AOM）, for the purpose of expanding our understanding of the role of fibrinolysis in the pathogene⁃
sis of AOM. Method Forty cases of OME（45 ears）were randomly selected to receive intratympanic administration
of Dexamethasone at 5 mg/ml（Group 1 or G1）, Batroxobin at 1 BU/ml（Group 2 or G2）or Batroxobin at 2 BU/ml
（Group 3 or G3）. Pre- and post-treatment changes in clinical symptoms, the Air conduction Hearing Threshold
（AHT）in pure tone audiometry and average AHT over 0.25 to 2 kHz were compared. Results Data from 31 cases
（33 ears）were available for analysis. AHTs among three groups were similar prior to treatment（P > 0.05）. The rate
of normal hearing following treatment in G3 was 70% or 7／10, higher than in G1（41.7% or 5／12）and G2（54.5%
or 6／11）（P < 0.05）. The rate of improvement following treatment was 81.8% or 9/11 and 80.0% or 8／10 in G2
and G3, respectively, higher than that in G1（50.0% or 6／12）（P < 0.05）. Conclusions Therapeutic effects of intra⁃
tympanic injection of Batroxobin on OME is superior to traditionally used Dexamethasone. In addition, higher concen⁃
tration of Batroxobin appears to be superior to lower concentrations. These findings confirm that fibrinolysis plays a
pivotal role in the pathogenesis of middle ear adhesion and that fibrinolytic medicine can prevent or reduce adhesion
development in the middle ear.
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Intruduction
Adhesive otits media（AOM）is an important cause of
hearing loss. Adhesion in the middle ear is irreversible
once formed. Therefore, the most effective clinical inter⁃
vention for AOM is to prevent or mitigate adhesion for⁃
mation in the middle ear. Currently, AOM is regarded as
a later stage or sequelae and complication of all types of
otitis media［1］. In the clinic, late stage otitis media with
effusion（OME）often is seen to progress to AOM, sup⁃
porting this view. Studies of peritoneal adhesion indi⁃
cate that reduction of local fibrinolysis is a key fac⁃
tor in peritoneal adhesion formation［2，3］. In addi⁃
tion, the characteristics of adhesion in the peritoneal
and tympanic cavities are similar. We, therefore, specu⁃
lated that fibrinolysis also played a pivotal role in mid⁃
dle ear adhesion［4］and hypothesized that, if so, the fibri⁃
nolytic medicine, Batroxobin, would prevent or reduce
adhesion formation and accelerate recovery from OME.
Here, we investigate the effect of Batroxobin on OME in
comparison to Dexamethasone, an agent widely used in
OME treatment, in order to elucidate the role of fibrino⁃
lysis during adhesion formation in the middle ear.
Material and Methods
1. Patient inclusion criteria: 1）reported fullness and
obstruction in the ear, hearing loss and tinnitus; 2）over
0.25-2kHz, air conduction hearing threshold（AHT）on
pure tone audiometry >25 dB HL, bone conduction ≤
25dB HL and air and bone gap ≥10 dB［5］；3）type
B or C tympanogram；4）presence of intratympanic flu⁃
id on tympanotomy；５）no other present diseases.
2. Treatment groups Patients were randomly selected
to receive intratympanic injection of dexamethasone so⁃
dium phosphate at 5 mg／ml（Group 1 or G1）, Batroxo⁃
bin（made in Japan）at 1 BU／ml（Group 2 or G2）or
Batroxobin at 2 BU／ml（Group 3 or G3）.
3. Patient data Of the 40 cases（45 ears）studied, 7
（10 ears）were excluded due to presence of sensorineu⁃
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Table.1 Patient data
Treatment Group
No. of Cases
Gender
No. of Ears
Age（year）
Disease Course
Male
Female
Left
Right
Total
Range
Mean
G1
10
7
3
5
7
12
10 - 70
37.7
1 days-20 years
G2
11
10
1
4
7
11
10 - 67
46.5
2 days-10 years
G3
10
9
1
4
8
12
10 - 68
35.6
3 days-15 years
ral component in their hearing loss and 2 cases（2 ears）
dropped from the study, resulting in 31 cases（33 ears）
meeting the inclusion criteria and enrolled in the study.
The distribution of age, gender and course of disease
were similar among the three treatment groups（see Ta⁃
ble 1）.
4. Treatment After sterilizing the external auditory me⁃
atus with 75% ethanol and topical tympanic membrane
anesthesia，tympanotomy was performed and the middle
ear drained. 0.5 ml of either dexamethasone sodium
phosphate at 5 mg／ml（G1）, Batroxobin at 1 BU／ml
（G2）or Batroxobin at 2 BU／ml（G3）was injected into
the tympanic cavity, After the procedure, patients were
placed on Cefalexin at 0.5 g tid for 5 days and followed
up on the 3rd, 7th, 14th and 28th post-operation days.
Treatment was repeated 1-2 times if deemed necessary.
AHT was tested before and after treatment.
5. Outcomes assessment
5.1 Efficacy assessment. Treatment efficacy was as⁃
sessed 4 weeks after treatment based upon AHT over
0.25 to 2 kHz and improvement of clinical symptoms.
The following criteria were used: 1）Complete resolu⁃
tion: AHT at all frequencies were <25 dB HL with no re⁃
sidual symptoms; 2）Significant improvement: AHT at
all frequencies improved by more than 30 dB with com⁃
plete resolution or significant improvement of clinical
symptoms; 3）Improvement: AHT at all frequencies im⁃
proved by 15 dB to 30 dB with noticeable symptom im⁃
provement; 4）Failure: AHT improvement was less than
15 dB with no symptom improvement［5］. The outcome
differences among groups were examined using χ2 test.
5.2 Audiometric data assessment. Pre- and post-treat⁃
ment AHT changes and differences in post-treatment
AHT among groups over 0.25 to 2 kHz were assessed us⁃
ing variance analysis.
Results
1. Symptoms: All but 2 ears in G1 showed complete
resolution or improvement of clinical symptoms.
2. Therapeutic effecacy: See Table 2-3 for changes in
symptoms and AHT over 0.25 to 2 kHz.
3. Audiometric data changes: See Table 3 and Figure
1 for AHT changes over 0.25 to 2 kHz in three groups
before and after treatment.
Groups
G1
G2
G3
Complete
ears
5
6
7
rate (%)
41.7
54.5
70.0**
Significant Improvement(ears)
0
0
0
Improvement(ears)
1
3
1
Failure（ears）
6
2
2***
Total Effecacy rate (%)
50.0*
81.8
80.0
Note: * G1 lower than G2 and G3（P< 0.05）; ** G3 higher than G1 and G2（P< 0.05）; *** Preoperative AHT were less than 30 dB HL in one of
the two failure cases in G3
Table.2 Treatment outcomes
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Note 1.Pr（pre-treatment）: no differences among the three groups
（Ｐ>0.05）
2. Po（post-treatment）: G3 lower than G2 and G1（Ｐ< 0.05), no differ⁃
ence between G2 and G1（Ｐ>0.05)
3. More pre- and post-treatment AHT change in G3 and G2 than in
G1（P<0.05）and no difference between G2 and G3 (Ｐ>0.05)
Groups
G1
G2
G3
0.25 kHz
Pr
30.4
34.5
34.5
Po
28.3
24.5
15.5
0.5 kHz
Pr
34.6
35.0
32.0
Po
26.7
19.5
15.0
1.0 kHz
Pr
37.5
40.9
36.0
Po
24.6
24.1
15.5
2.0 kHz
Pr
27.1
34.5
31.5
Po
21.3
20.5
16.0
Table.3 Pre- and post-treatment AHT (dB HL)
Discussion
According to reports, decreased local fibrinolysis plays
a pivotal role in the pathogenesis of peritoneal adhesions
［2，3］. As the activity of plasminogen activator（PA）, the
most important factor in fibrinolysis, in effusion of the
middle ear, is reduced ［6, 7］，Effective prevention and
treatment of OME with the fibrinolysis medicine, Ba⁃
troxobin［8］, have been reported in an experimental model
and the authors’previous works have shown that PA
plays a role in adhesive formation in the middle ear ［9］，
we hypothesize, therefore, that fibrinolysis is also an im⁃
portant factor in the pathogenesis of middle ear adhesion
through mechanisms similar to that in peritoneal adhe⁃
sion. Adhesion formation can be caused by many fac⁃
tors, including infection, allergy, surgery, injury, eusta⁃
chian tube dysfunction, etc. Damage to the mucosa of
middle ear leads to inflammatory responses and repair
which involve several complex biological processes and
at least five separate, but interrelated, systems. Mucosal
damage can result in injury of vascular endothelium
and subsequent exudation of all blood constituents, in⁃
cluding fibrinogen, plasminogen and fibronectin（Fn）,
all of which can collect in the middle ear. Fibrinogen re⁃
acts with thrombin to create fibrin monomer that can po⁃
lymerize. Fibrin polymers then come into contact with
coagulation factors such as factor XIIIa and become in⁃
soluble. Eventually, insoluble fibrin polymers interact
with large proteins, such as Fn, to produce the fibrin gel
matrix. Adhesion formation or adhesion-free re-epitheli⁃
alization of the fibrin matrix is an alternative pathway,
which depends on fibrinolytic activities. At sufficient
levels of fibrinolytic activities, the fibrin gel matrix can
be completely lysed. Otherwise, the fibrin gel matrix re⁃
mains and serves as the progenitor to adhesions by form⁃
ing a band or bridge between two apposed mucosa sur⁃
faces coated with it. The band or bridge becomes the ba⁃
sis for the organization of an adhesion. Usually, within 5
to 7 days, it can be determined whether the fibrin gel
matrix has persisted or been lysed［2-4］, consistent with
findings in animal models of middle ear adhesion forma⁃
tion［10］.
There are three sources of fluid in OME: blood con⁃
tents from the middle ear mucosa discharged into the
cavity, secretions arising from mucosa epithelium meta⁃
plasia, and proliferation of mucosa glands. Related to
the first source are three models of pathogenesis based
on blood vessel permeability: 1) bubble proliferation, 2)
loosening contact between endothelial cells, and 3) endo⁃
thelium destruction. In mild cases, the first two condi⁃
tions preponderate and the exudation consists of salt and
low molecular weight proteins. In severe cases where the
third circumstance occurs, a great variety of blood com⁃
ponents can be exuded［11］. The latter two fluid source
of OME typify chronic reactions where the aforemen⁃
tioned blood vessel reaction underlies and persists
throughout the inflammation process.
Fibrin（coming from fibrinogen）deposition in the mid⁃
dle ear seems to be a prerequisite for adhesion forma⁃
tion. Fibrinogen comes from the blood during the inflam⁃
matory process and is a high molecular weight protein. It
is exuded in severe cases that destroy the vessel’s endo⁃
Fig.1 Average pr-and post-treatment AHT changes over
0.25 to 2 kHz. Solid lines: pre-treatment, and dashed lines:
post-treatment. There are more pre- and post-treatment
AHT changes in G3 and G2 than in G1（P< 0.05）and no dif⁃
ference between G2 and G3（P> 0.05）
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thelial cells. The quantity of high molecular weight pro⁃
teins released during effusion, such as fibrinogen and
Fn, varies based upon the extent of mucosa damage,
thus the varying degrees of development of adhesion in
the middle ear.
Once formed, adhesion is irreversible. Giving medi－
cines that promote fibrinolysis to decompound fibrino⁃
gen and dissolve gel matrix before adhesion develop⁃
ment can prevent or reduce adhesion in OME, as well as
accelerating recovery.
The current work compared the therapeutic effects be⁃
tween Batroxobin and Dexamethasone. The conditions of
the three groups in this study were similar, exhibiting
equivalent hearing loss（P >0.05）. Medical intervention
prior to entering the study was also comparable as was
the study methodology, allowing studying effects from
pharmacological differences between the two medica⁃
tions. The main role of Batroxobin is to promote fibrino⁃
lysis, which is realized by decomposing fibrinogen, pro⁃
moting the release and activity of tissue PA（tPA）, and
reducing its inhibitors, such as а2－ PI, PAI［12］. Dexa⁃
methasone works through its anti-inflammatory, antitox⁃
ic and antishock capabilities and through inhibition of
growth of capillaries and fibroblasts, which can prevent
adhesion development at later stages of inflammation.
Our results indicate that therapeutic effects of Batroxo⁃
bin are better than those of Dexamethasone on OME,
and that Batroxobin at 2 BU/ml is superior to Batroxobin
at 1 BU/ml. This suggests that fibrinolysis is a major fac⁃
tor in middle ear adhesion formation and pathogenesis of
AOM and those Batroxobin-like medicines may prevent
or reduce adhesion development in the middle ear.
We therefore conclude that fibrinolysis is an important
factor in pathogenesis of middle ear adhesion and that
application of medicines that promote fibrinolytic pro⁃
cess and removing exuded fibrinogen in the middle ear
in time can prevent／reduce adhesion formation and de⁃
velopment of AOM.
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